Saturday, July 23, 2016

TIM KAINE--The Big Zika Payoff--INTREXON DC LOBBY

TO YESENIA
FROM  PICASSO
SUBJ  MOSQUITOS $ MONEY--

(SANTA CLARITA BUREAU)--Note a big campaign contributor to Kaine's PAC that set himself up for governor, in particular, the top donor, RJ Kirk $685,000

http://www.vpap.org/committees/135776/moving-virginia-forward/
RJ Kirk= $685,000

http://www.readthehook.com/108684/kirk-departs-contributions-politicians-exceeded-gifts-uva
Kirk does, however, have a penchant for making money– and then giving chunks of it to governors. While a summertime Freedom of Information request found that Kirk had donated $60,000 to UVA, his donations to governors far surpass that.
According to data from the Virginia Public Access project, Kirk and his companies gave $940,000 to the man who appointed him, Tim Kaine.

Here's the CNBC report on the angle--

http://www.cnbc.com/2016/05/13/intrexon-ceo-believe-well-get-ok-to-combat-zika-in-us.html
Intrexon will ultimately get approval to combat the Zika virus in the United States, its chief executive predicted Friday.
The biotech company's subsidiary Oxitec has produced genetically modified mosquitoes that can be used to compete with normal Aedes aegypti mosquitoes that transmit the virus. Oxitec's mosquitoes can stop the spread of Zika by passing along a gene to their offspring that makes them die young.
CEO R.J. Kirk said he's spent the past several days in Washington pressing his case.
"I'm now very sanguine that we will have approval in the U.S. eventually because I see that the leadership in the U.S. is coalescing around the idea … that we really need to eliminate or at least vastly reduce the population of the Aedes aegypti mosquito and I think they are really starting to get our technology,"





And here's the Motley Fool take on the company--

http://www.fool.com/investing/general/2016/05/03/is-intrexon-really-a-house-of-cards.aspx

Acquired revenue 1, Organic revenue 0While there are some misrepresentations and errors in the report, it also sheds light on some pretty damning evidence supporting several arguments -- namely, that Intrexon's core technology suite, consisting primarily of molecular biology tools for cell and organism engineering, has yet to contribute in any meaningful way to, well, anything. The lack of use is actually among the worst-kept secrets in the engineered biology field -- the technology hasn't had nearly the impact one would expect from a market leader, despite what the company continuously touts.





DIST YESENIA, FATIMA & NANCY N...











..

No comments:

Post a Comment